Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report issued on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a hold rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Agile Therapeutics Trading Down 13.4 %

NASDAQ:AGRX opened at $0.36 on Friday. The company has a 50-day moving average price of $0.74 and a 200-day moving average price of $1.50. The stock has a market cap of $2.50 million, a price-to-earnings ratio of -0.04 and a beta of 1.42. Agile Therapeutics has a 12 month low of $0.20 and a 12 month high of $8.73.

Institutional Trading of Agile Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in Agile Therapeutics by 1.1% during the 1st quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock valued at $319,000 after acquiring an additional 16,104 shares during the period. Renaissance Technologies LLC increased its stake in shares of Agile Therapeutics by 281.3% during the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Agile Therapeutics during the fourth quarter valued at approximately $32,000. Armistice Capital LLC lifted its holdings in shares of Agile Therapeutics by 10.2% during the fourth quarter. Armistice Capital LLC now owns 108,000 shares of the specialty pharmaceutical company’s stock valued at $211,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Agile Therapeutics in the 2nd quarter worth approximately $108,000. 10.92% of the stock is owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.